News | July 19, 2011

First Use of Freedom Portable Driver to Power Artificial Heart Published


July 19, 2011 — An article published in the July issue of the Journal of Heart and Lung Transplantation reports the first use of the Freedom portable driver with a Total Artificial Heart (TAH-t) patient. The TAH-t is manufactured by SynCardia Systems Inc.

“TAH-t use has been limited by the large operating console for the driver system that requires patients to remain hospitalized until transplantation,” wrote the article’s authors. “The Freedom driver allows clinically stable patients to await a donor heart as an outpatient.”

The patient, 41, was implanted with the TAH-t on Sept. 3, 2008 after his body rejected the donor heart he'd received at age 30. For more than 600 days, he was confined to the hospital by the 418-lb "Big Blue," the only U.S. Food and Drug Administration (FDA)-approved driver for powering the TAH-t. Due to the previous transplant, the patient’s body produced antibodies that made it challenging for him to receive a matching donor heart.

In March 2010, SynCardia received approval from the FDA to conduct an investigational device exemption (IDE) clinical study of the Freedom driver, the first U.S. portable driver designed to power the TAH-t both inside and outside the hospital. On May 3, 2010, this patient was discharged from the hospital to wait for a matching donor heart at home with his wife and children. He was supported by the Freedom driver for a total of 253 days before receiving a dual heart and kidney transplant on Jan. 15, 2011.

“The success of our first patient to be discharged home and then undergo transplantation is encouraging,” concluded the article’s authors. “Out-of-hospital management of the patient with a TAH-t appears feasible, and consideration for use of this device for longer-term applications may be held in the future.”

To date, the hospital has transferred six TAH-t patients to the Freedom portable driver while awaiting heart transplantation. The driver is also CE approved for use in Europe.

For more information: www.syncardia.com


Related Content

News | Ventricular Assist Devices (VAD)

October 31, 2023 — Tenaya Therapeutics, Inc., a clinical-stage biotechnology company with a mission to discover, develop ...

Home October 31, 2023
Home
News | Ventricular Assist Devices (VAD)

June 7, 2023 — Magenta Medical Ltd. has announced the initiation of its FDA-approved Early Feasibility Study with the ...

Home June 07, 2023
Home
News | Ventricular Assist Devices (VAD)

March 1, 2023 — Mesoblast Limited, global leader in allogeneic cellular medicines for inflammatory diseases, today ...

Home March 01, 2023
Home
News | Ventricular Assist Devices (VAD)

November 2, 2022 — For decades, left ventricular-assist devices (LVADs) have extended the lives of people whose hearts ...

Home November 02, 2022
Home
News | Ventricular Assist Devices (VAD)

October 18, 2022 — The U.S. Food and Drug Administration (FDA) is providing updates to the FDA website to include ...

Home October 18, 2022
Home
News | Ventricular Assist Devices (VAD)

August 25, 2022 — The U.S. Food and Drug Administration (FDA) issued a statement that Medtronic, Inc. is recalling ...

Home August 25, 2022
Home
News | Ventricular Assist Devices (VAD)

August 5, 2022 — Black people and women with severe heart failure who might be good candidates for surgery to implant a ...

Home August 05, 2022
Home
News | Ventricular Assist Devices (VAD)

June 23, 2022 — Medtronic, Inc. is recalling a single lot of HeartWare HVAD System batteries due to welding defects that ...

Home June 23, 2022
Home
News | Ventricular Assist Devices (VAD)

June 8, 2022 — The U.S. Food and Drug Administration (FDA) has issued a release stating that Medtronic is recalling the ...

Home June 08, 2022
Home
News | Ventricular Assist Devices (VAD)

April 28, 2022 — The U.S. Food and Drug Administration (FDA) is alerting healthcare providers to the possibility that ...

Home April 28, 2022
Home
Subscribe Now